Carl L. G. Hansen - 01 Jan 2025 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share option (right to buy)	Award	$0	+2,730,109	+33%	$0.000000	10,990,332	01 Jan 2025	Common Shares	2,730,109	$2.93	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date